Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Three-Year Exclusivity Questioned By Sen. Edwards, GPHA’s Jaeger

This article was originally published in The Tan Sheet

Executive Summary

Sen. John Edwards (D-N.C.) may be interested in re-examining the three-year market exclusivity provision under Hatch/Waxman as discussion on generic drug reform moves forward on Capitol Hill

You may also be interested in...



Generic Delay Tactics Evolving In Wake Of Consent Decrees – Initial FTC Data

Potentially anticompetitive strategies on generics have evolved since the Federal Trade Commission began imposing consent agreements on companies that made questionable settlements, FTC states

Generic Delay Tactics Evolving In Wake Of Consent Decrees – Initial FTC Data

Potentially anticompetitive strategies on generics have evolved since the Federal Trade Commission began imposing consent agreements on companies that made questionable settlements, FTC states

Generic Delay Tactics Evolving In Wake Of Consent Decrees – Initial FTC Data

Potentially anticompetitive strategies on generics have evolved since the Federal Trade Commission began imposing consent agreements on companies that made questionable settlements, FTC states

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS094014

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel